Broadly protective human antibodies that target the active site of influenza virus neuraminidase
Daniel Stadlbauer(Icahn School of Medicine at Mount Sinai), Florian Krammer(Semmelweis University), Ali H. Ellebedy(Washington University in St. Louis), Shirin Strohmeier(Icahn School of Medicine at Mount Sinai), Aaron J. Schmitz(Washington University in St. Louis), Philip A. Mudd(Washington University in St. Louis), Meagan McMahon(Seqirus (United States)), Jackson S. Turner(Washington University in St. Louis), Xueyong Zhu(Scripps Research Institute), Wenli Yu(Scripps Research Institute), Ian A. Wilson(Raigmore Hospital), Teddy John Wohlbold(Morgan Stanley Children's Hospital), Raffael Nachbagauer(Moderna Therapeutics (United States))
Cited by 289
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
|Science|2013|826